• July 2, 2015

    Flaum Eye Institute Scientist Gets Funding to Study Vision Loss in Batten Disease

    Ruchira Singh, Ph.D.

    University of Rochester Medical Center scientist Ruchira Singh, Ph.D., received a grant from the Knights Templar Eye Foundation to investigate how neurodegenerative diseases, such as juvenile Batten disease, cause blindness.

    Singh, assistant professor of Ophthalmology and Biomedical Genetics, will use the $60,000 grant to create a human model of Batten disease (CNL3) using patient’s own cells. The project may lead to better understand the disease mechanisms, aiding in the development of drug therapies to preserve vision in affected patients.

    For the complete article, visit the URMC newsroom.

  • December 18, 2013

    Workshop on JNCL Clinical Trials Outcomes

    There are a number of recent and ongoing clinical trials in Batten Disease. Most of these are focused on asking if these potential new treatments are safe. After safety studies are completed, the next stage of clinical trials research is to learn if these or other interventions are effective. In order to answer this question, we will need a way to measure whether or not an intervention actually makes a meaningful difference in disease course.

    Therefore, the URBC hosted a workshop titled, Outcome Measures and Infrastructure for Phase III Studies in JNCL (December 6-7, 2013). The workshop brought together experts in the clinical features of JNCL, experts from other fields (clinical trials in rare diseases, statistics, etc.), and Batten family representatives. Each expert was invited to bring trainee to accompany him/her, so that we can continue cultivating the next generation of researchers who are focused on Batten Disease. Our goals were to:

    • Identify possible outcome measures for future clinical trials
    • Develop a roadmap for further research to test and refine outcome measures
    • Strengthen research collaborations to support outcome measure development
  • November 1, 2013

    Clinical Trial for Children with Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)

    The University of Rochester Medical Center is currently recruiting subjects with JNCL for a clinical trial. This research study will focus on evaluating whether an investigational drug is safe and well tolerated in children with JNCL. Mycophenolate mofetil (also known as Cellcept) is a medication that suppresses the immune system. The study is 22 weeks long with a total of 8 in-person visits and 4 telephone contacts. Four visits require travel to University of Rochester Medical Center in Rochester, New York, and four visits are with your child’s local physician. Four contacts take place by telephone. Travel costs are covered by the study. Children enrolled in the study will take mycophenolate syrup twice a day, and will have blood drawn at each study visit to monitor safety.

    More information on the trial can be found at, Time Warner Cable News (Rochester, NY television affiliate) and the URMC Newsroom.

    For further information, please contact Amy Vierhile at (585) 275-4762.